Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAMSA2020
2022-502392-37-00Phase 2Completed
- Sponsor
- French Innovative Leukemia Organization
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in acute myeloid leukemia (AML) comparing venetoclax + cytarabine with idarubicin + cytarabine (2 arms). Started Jul 2024; status: completed.
02
Drugs
venetoclaxidarubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2022-502392-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502392-37-00.